NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 02:20PM ET
1.33
Dollar change
+0.02
Percentage change
1.53
%
Index- P/E- EPS (ttm)-0.86 Insider Own56.58% Shs Outstand48.26M Perf Week-0.75%
Market Cap64.19M Forward P/E- EPS next Y-0.75 Insider Trans0.00% Shs Float20.95M Perf Month-1.48%
Enterprise Value-43.25M PEG- EPS next Q-0.13 Inst Own33.21% Short Float0.39% Perf Quarter6.40%
Income-41.71M P/S- EPS this Y46.08% Inst Trans10.09% Short Ratio0.87 Perf Half Y-16.87%
Sales0.00M P/B0.54 EPS next Y-36.36% ROA-27.47% Short Interest0.08M Perf YTD-18.90%
Book/sh2.45 P/C0.56 EPS next 5Y-0.00% ROE-30.49% 52W High1.94 -31.44% Perf Year-19.39%
Cash/sh2.36 P/FCF- EPS past 3/5Y-2.47% -16.81% ROIC-34.48% 52W Low0.97 37.01% Perf 3Y-71.70%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility2.69% 4.04% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM45.20% Oper. Margin- ATR (14)0.06 Perf 10Y-
Dividend Ex-Date- Quick Ratio13.31 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)51.66 Recom2.00
Dividend Gr. 3/5Y- - Current Ratio13.31 EPS Q/Q46.62% SMA20-2.60% Beta0.50 Target Price2.00
Payout- Debt/Eq0.06 Sales Q/Q- SMA505.90% Rel Volume0.11 Prev Close1.31
Employees10 LT Debt/Eq0.02 EarningsMay 08 SMA200-9.11% Avg Volume92.81K Price1.33
IPOMar 26, 2021 Option/ShortNo / Yes EPS/Sales Surpr.-3.47% - Trades Volume7,798 Change1.53%
Date Action Analyst Rating Change Price Target Change
May-29-24Downgrade Wedbush Outperform → Neutral $8 → $2
Sep-22-23Initiated Wedbush Outperform $11
May-04-23Resumed H.C. Wainwright Buy $18
Dec-23-21Initiated H.C. Wainwright Buy $25
May-05-21Resumed Credit Suisse Outperform $30
Apr-26-21Resumed Credit Suisse Outperform $30
Apr-20-21Initiated William Blair Outperform
Apr-20-21Initiated Jefferies Buy
Apr-20-21Initiated Credit Suisse Outperform $30
Mar-28-25 04:30PM
Dec-30-24 12:00PM
Dec-24-24 08:58AM
Dec-23-24 08:37AM
Nov-07-24 08:30AM
04:15PM Loading…
Aug-08-24 04:15PM
May-29-24 07:39AM
May-28-24 04:42PM
04:15PM
May-13-24 08:52PM
04:45PM
Apr-10-24 08:00AM
Mar-12-24 08:00AM
Feb-27-24 08:00AM
Feb-21-24 04:15PM
09:35AM Loading…
Feb-14-24 09:35AM
Jan-24-24 09:35AM
Jan-19-24 06:25AM
Jan-18-24 04:05PM
Nov-09-23 07:00AM
Nov-07-23 08:00AM
Sep-27-23 09:01AM
Sep-05-23 08:00AM
Aug-12-23 08:07AM
Aug-10-23 09:30AM
08:00AM
06:08AM
Aug-08-23 08:24AM
Aug-07-23 07:00AM
Jun-20-23 08:50AM
02:59PM Loading…
Jun-05-23 02:59PM
Jun-02-23 08:50AM
May-24-23 08:00AM
May-16-23 08:29AM
May-15-23 09:05AM
07:50AM
07:45AM
06:01AM
May-10-23 05:35PM
08:42AM
May-08-23 12:07PM
May-04-23 09:00PM
May-03-23 08:50AM
May-02-23 09:29PM
Apr-20-23 08:00AM
Apr-17-23 09:00AM
06:48AM
Mar-14-23 08:15AM
07:00AM
Mar-07-23 08:00AM
Mar-06-23 08:00AM
Mar-01-23 07:13AM
Feb-28-23 08:00AM
Dec-22-22 07:13AM
Dec-19-22 04:30PM
Nov-28-22 12:11PM
08:00AM
Nov-22-22 07:30AM
Nov-11-22 10:05AM
Nov-10-22 09:00AM
Nov-07-22 09:25AM
08:48AM
08:05AM
Oct-26-22 07:30AM
Oct-18-22 07:30AM
Oct-05-22 08:05AM
Sep-22-22 06:25AM
Sep-06-22 07:30AM
Aug-12-22 07:41AM
Aug-11-22 08:45AM
07:30AM
Jul-14-22 10:43AM
Jul-06-22 07:00AM
Jun-22-22 07:00AM
Jun-14-22 09:13AM
May-18-22 07:00AM
May-15-22 08:41AM
May-13-22 08:28AM
May-12-22 08:35AM
07:00AM
May-11-22 08:44AM
07:32AM
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-13-22 07:00AM
Apr-12-22 02:01PM
Mar-28-22 05:37PM
Mar-17-22 07:00AM
Mar-07-22 04:30PM
Mar-01-22 07:00AM
Feb-03-22 04:35PM
Jan-26-22 07:00AM
Dec-24-21 12:38AM
Dec-23-21 06:05AM
Dec-18-21 12:38AM
Dec-17-21 08:00AM
Dec-08-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 07:00AM
Nov-04-21 07:00AM
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.